The "KEY OF HOPE" program is aimed at increasing the awareness of patients about the disease and reducing the cost of therapy for the patient with drugs included in the Program, intended for the treatment of certain types of oncological diseases by influencing the immune system;
Preparation of the project:
KITRUDA® (pembrolizumab)
Keytruda conc. d/r-nu d/inf. 25 mg/ml fl. 4 ml No. 1
The promotion is held until: 31.12.2025
You can learn more about the terms of participation in the project on the website: https://medicard.com.ua/medicard/page/key_hope_ruless/
The "Asakard" program was developed by the Biocodex company in order to ease your burden during the long-term treatment of intestinal diseases.
Drugs:
ASAKOL® coated tablets, enteric-soluble 800 mg No. 60;
ASAKOL® coated tablets, enteric-soluble 400 mg No. 100;
ASAKOL® rectal suppositories of 500 mg No. 20.You can learn more about the terms of participation in the project on the website:https://privit.com.ua/asacard/
"CHERVONA KALINA"
The goal of the Program is to improve access of Ukrainian patients to effective innovative treatment with medicines included in the Program.
The program is valid from October 1, 2023 to March 31, 2028 inclusive.
The patient support program "CHERVONA KALYNA" is implemented by Astellas Pharma LLC with information and technical support from Medicard LLC
More information about the conditions for participation in the project can be found on the project website.
The "About Peace" program is designed to increase the availability of quality medicines included in the Program for the treatment of psychosomatic anxiety disorder in adult patientsThe program is valid from November 1, 2025 to December 31, 2026 inclusive.More information about the conditions for participation in the project can be found on the project website
AFFORDABLE PROTECTION OF THE LIVER AND GALLBLADDER
The hepatobiliary system includes the liver, gallbladder, intrahepatic and extrahepatic bile ducts. Functional disorders of the hepatobiliary system occupy a significant place among diseases of the gastrointestinal tract. Pathologies associated with the formation and secretion of bile are especially common.High-quality treatment of disorders of the hepatobiliary system increases the chances of a full recovery and prevents the appearance of complications.
If your doctor has prescribed you a medicine that is part of the "AFFORDABLE PROTECTION OF THE LIVER AND GALLBLADDER" program, you can become its participant and receive medicines included in the Program at a discount at partner pharmacies.
More information about the conditions for participation in the project can be found onthe project website.
The patient support program aims to make treatment of patients with heart failure with reduced ejection fraction more accessible
The program "PATH TO A HEALTHY HEART" is implemented on the initiative of PJSC "PHARMACEUTICAL COMPANY "DARNYTSYA" with the technical support of LLC "MEDYCARD PLUS"
More details about the terms of participation in the project can be found on the project website
Patient Support Program "Free Movement Without Pain"
The social patient support program aims to increase awareness and accessibility of therapies for the treatment of patients with joint pain.
Information can be found on the website https://medicard.com.ua/medicard/page/movement_wo_pain/
Take control of your blood pressure
The social patient support program aims to make quality antihypertensive therapy more accessible.
Information can be found on the website https://medicard.com.ua/medicard/page/control_your_pressure/
Migraine is not a sentence
The social patient support program aims to increase awareness and accessibility of therapy for the treatment of patients with migraine.
Information can be found on the website https://medicard.com.ua/medicard/page/migraine_not_doom/
the company is focused on the key needs in healthcare, the development of new medicines, technologies and treatments. This is an international diversified company operating in the health sector. Time-tested products are highly appreciated by experts worldwide for its efficiency, reliability and safety. Program Time (ABBOTT CARDS ) provides the opportunity to purchase efficient medications at a more affordable price.
Drugs project:
Heptral since.lyophil.d/R-RA d/INF.500mg FL., No. The 5+solution.amp.5ml No. 5
Heptral tab.enteric solution.500 mg No. 20More details about conditions of participation in the project can be found on the project website Abbott cards
Darnitsa is a pharmaceutical company, a leader in Ukrainian market in the production and physical sales of prescription (Rx) and over-the-counter (OTC) generic products. The company began operating in 1930. In 2019, Darnitsa rebranded and announced a new business strategy: to transform based on digital technologies, to build an international brand and to lead in the generic segment of medicines.
The company's portfolio includes 280 names of ready-to-use drugs. Darnitsa focuses on the treatment of cardiac, neurological diseases and pain. Its products are exported to 16 countries.
The Darnitsa plant in Kyiv has 14 production lines certified according to the GMP standard.
Farmak is the leader of pharmaceutical market with a share of 5.9 %. The medicines of all fourteen therapeutic groups are produced at the factory. Among the main areas are anti-cold, endocrinological, gastroenterological, cardiological and neurological portfolios. Every year, Farmak launches approximately 20 new drugs on the market; these are complex modern medications needed by millions of people, both in our country and abroad. About a hundred drugs are currently under development.
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, respiratory diseases.
Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organization covers almost all key European markets and a few Southeast Asian countries. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
“PLUS Therapy” – the program aims to support patients with chronic diseases in areas such as cardiology, endocrinology, pneumology, psychiatry and Oncology. For each Drug, which participates in the Program, define an appropriate charging scheme discounts. The discount is given to cardholders ‘Terapias”, which are issued to patients who had been prescribed the drug involved in the Program “Terapias”, by a doctor of the healthcare institution.
Drugs project:
Ось переклад англійською мовою:
Brilinta film-coated tablets 90 mg No. 56
Brilinta film-coated tablets 60 mg No. 56
Kombiglyze XR film-coated tablets 5 mg / 1000 mg No. 28
Crestor film-coated tablets 10 mg No. 28
Crestor film-coated tablets 20 mg No. 28
Crestor film-coated tablets 40 mg No. 28
Crestor film-coated tablets 5 mg No. 28
Onglyza film-coated tablets 5 mg No. 30
Xigduo XR prolonged-release film-coated tablets 10 mg / 1000 mg No. 28
Xigduo XR prolonged-release film-coated tablets 5 mg / 1000 mg No. 28
Trixeo Aerosphere pressurized inhalation suspension 5 / 7.2 / 160 mcg, 120-dose canister No. 1
More details about conditions of participation in the project can be found on the project website Therapy PLUS
